Pulmonary hypertension (PH) in patients with
chronic lung disease (CLD) and/or hypoxia is a significant complication, linked
to increased morbidity and mortality. CLD-associated PH (Group 3 PH) commonly
arises in conditions such as chronic obstructive pulmonary disease (COPD),
interstitial lung disease (ILD), hypoventilation syndromes, and other hypoxic
disorders. Patients with CLD-PH often present with dyspnea, chest discomfort,
and poor quality of life, and frequently require oxygen therapy or mechanical
ventilation
摘要檔案: AB all.pdf